Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study

Correll, Christoph U.; Robinson, Delbert G.; Schooler, Nina R.; Brunette, Mary F.; Mueser, Kim T.; Rosenheck, Robert A.; Marcy, Patricia; Addington, Jean; Estroff, Sue E.; Robinson, James; Penn, David L.; Azrin, Susan; Goldstein, Amy; Severe, Joanne; Heinssen, Robert; Kane, John M.

doi:10.1001/jamapsychiatry.2014.1314

Cited by 384Schizophrenia research and treatmentDiabetes, Cardiovascular Risks, and LipoproteinsHIV-related health complications and treatments

Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study

Correll, Christoph U., Robinson, Delbert G., Schooler, Nina R., Brunette, Mary F., Mueser, Kim T., Rosenheck, Robert A., Marcy, Patricia, Addington, Jean +8 more·2014·JAMA Psychiatry

DOI 10.1001/jamapsychiatry.2014.1314

Open this paper in CoChat — free account

Abstract

IMPORTANCE: The fact that individuals with schizophrenia have high cardiovascular morbidity and mortality is well established. However, risk status and moderators or mediators in the earliest stages of illness are less clear. OBJECTIVE: To assess cardiometabolic risk in first-episode schizophrenia spectrum disorders (FES) and its relationship to illness duration, antipsychotic treatment duration and type, sex, and race/ethnicity. DESIGN, SETTING, AND PARTICIPANTS: Baseline results of the Recovery After an Initial Schizophrenia Episode (RAISE) study, collected between July 22, 2010, and July 5, 2012, from 34 community mental health facilities without major research, teaching, or clinical FES programs. Patients were aged 15 to 40 years, had research-confirmed diagnoses of FES, and had less than 6 months of lifetime antipsychotic treatment. EXPOSURE: Prebaseline antipsychotic treatment was based on the community clinician's and/or patient's decision. MAIN OUTCOMES AND MEASURES: Body composition and fasting lipid, glucose, and insulin parameters. RESULTS: In 394 of 404 patients with cardiometabolic data (mean [SD] age, 23.6 [5.0] years; mean [SD] lifetime antipsychotic treatment, 47.3 [46.1] days), 48.3% were obese or overweight, 50.8% smoked, 56.5% had dyslipidemia, 39.9% had prehypertension, 10.0% had hypertension, and 13.2% had metabolic syndrome. Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent. Total psychiatric illness duration correlated significantly with higher body mass index, fat mass, fat percentage, and waist circumference (all P<.01) but not elevated metabolic parameters (except triglycerides to HDL-C ratio [P=.04]). Conversely, antipsychotic treatment duration correlated significantly with higher non-HDL-C, triglycerides, and triglycerides to HDL-C ratio and lower HDL-C and systolic blood pressure (all P≤.01). In multivariable analyses, olanzapine was significantly associated with higher triglycerides, insulin, and insulin resistance, whereas quetiapine fumarate was associated with significantly higher triglycerides to HDL-C ratio (all P≤.02). CONCLUSIONS AND RELEVANCE: In patients with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other. Prevention of and early interventions for psychiatric illness and treatment with lower-risk agents, routine antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earliest illness phases.

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2014.1314

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In patients with first-episode schizophrenia spectrum disorders, cardiometabolic risk factors were present early in the illness, related to the underlying disorder, unhealthy lifestyle and antipsychotic medications, which interact with each other.
“In patients with first-episode schizophrenia spectrum disorders, cardiometabolic risk factors were present early in the illness; this was related to the underlying disorder, unhealthy lifestyle and antipsychotic medications, which interact with each other.437”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [437]

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Chobanian, A., Bakris, G., Black, H., Cushman, W., Green, L., Izzo, J., Jones, D. W., Materson, B., Oparil, S., Wright, J. T., et al. (2003) · Journal of the American Medical Association (JAMA) · doi:10.1097/00132578-200307000-00027 · Cited by 26,188 · see citing works
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386 · see citing works
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961 · see citing works
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · see citing works
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470 · see citing works
Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058 · see citing works
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · see citing works
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Prevalence of a Metabolic Syndrome Phenotype in Adolescents: Findings From the Third National Health and Nutrition Examination Survey, 1988-1994
Cook, S., Weitzman, M., Auinger, P., Nguyen, M., & Dietz, W. H. (2003) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.157.8.821 · Cited by 2,326 · see citing works
The Metabolic Syndrome: Prevalence and Associated Risk Factor Findings in the US Population From the Third National Health and Nutrition Examination Survey, 1988-1994
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074 · see citing works
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · see citing works
Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses—United States, 1997–2001
Tanoue, L. T. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70176-7 · Cited by 1,413 · see citing works
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 1,321 · see citing works
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.
(2006) · Europe PMC (PubMed Central) · Cited by 1,299 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088 · see citing works
Mortality Risk Reduction Associated With Smoking Cessation in Patients With Coronary Heart Disease
Critchley, J., & Capewell, S. (2003) · JAMA · doi:10.1001/jama.290.1.86 · Cited by 1,086 · see citing works
Association of socioeconomic position with health behaviors and mortality
Stringhini, S. (2010) · JAMA · doi:10.1001/jama.2010.297 · Cited by 1,065 · see citing works
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · see citing works
Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses—United States, 2000-2004
(2009) · JAMA · doi:10.1001/jama.301.6.593 · Cited by 946 · see citing works
Prevalence of Major Cardiovascular Risk Factors and Cardiovascular Diseases Among Hispanic/Latino Individuals of Diverse Backgrounds in the United States
Daviglus, M. L., Talavera, G. A., Avilés-Santa, L. M., Allison, M., Cai, J., Criqui, M. H., Gellman, M. D., Giachello, A. L. M., Gouskova, N., Kaplan, R. C., et al. (2012) · JAMA · doi:10.1001/jama.2012.14517 · Cited by 911 · see citing works
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Howard, W. J. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70316-0 · Cited by 905 · see citing works
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870 · see citing works
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
Buchanan, R., Kreyenbuhl, J., Kelly, D., Noel, J. M., Boggs, D., Fischer, B., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia bulletin · doi:10.1093/schbul/sbp116 · Cited by 844 · see citing works
Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden
Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778 · see citing works
Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714 · see citing works
Adolescent BMI Trajectory and Risk of Diabetes versus Coronary Disease
Tirosh, A., Shai, I., Afek, A. B., Dubnov‐Raz, G., Ayalon, N., Gordon, B., Derazne, E., Tzur, D., Shamis, A., Vinker, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006992 · Cited by 705 · see citing works
Is There a Simple Way to Identify Insulin-Resistant Individuals at Increased Risk of Cardiovascular Disease?
McLaughlin, T., Reaven, G. M., Abbasi, F., Lamendola, C. A., Saad, M. F., Waters, D. D., Simon, J., & Krauss, R. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.085 · Cited by 659 · see citing works
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200209000-00017 · Cited by 580 · see citing works
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Nasrallah, H. A., Meyer, J. M., GOFF, D. C., McEvoy, J. P., Thomas, S., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 553 · see citing works
Understanding Excess Mortality in Persons With Mental Illness
Druss, B. G., Zhao, L., von Esenwein, S. A., Morrato, E. H., & Marcus, S. C. (2011) · Medical Care · doi:10.1097/mlr.0b013e31820bf86e · Cited by 438 · see citing works
Increased Mortality Among Patients Admitted With Major Psychiatric Disorders: A Register-Based Study Comparing Mortality in Unipolar Depressive Disorder, Bipolar Affective Disorder, Schizoaffective Disorder, and Schizophrenia
Laursen, T. M., Munk-Olsen, T., Nordentoft, M., & Mortensen, P. B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0612 · Cited by 380 · cited 2× · see citing works
“Patients and Treatment The following were inclusion criteria for the patients: (1) being aged 15 to 40 years (1 patient was aged 51 years; a protocol exception was filed); (2) being diagnosed as having schizophrenia, schizophreniform disorder, schizoaffective disorder, psychotic disorder not otherwise specified, or br…”
Background
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · see citing works
Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey
McClave, A. K., McKnight-Eily, L. R., Davis, S. P., & Dube, S. R. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.188136 · Cited by 339 · see citing works
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332 · see citing works
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Mitchell, A. J., Vancampfort, D., Herdt, A. D., Yu, W., & Hert, M. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 331 · see citing works
Glucose-Independent, Black–White Differences in Hemoglobin A <sub>1c</sub> Levels: A Cross-sectional Analysis of 2 Studies
Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Twombly, J. G., Narayan, K. M. V., Koch, D. D., & Phillips, L. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-12-201006150-00004 · Cited by 326 · see citing works
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 307 · see citing works
Vital signs: current cigarette smoking among adults aged ≥18 years with mental illness - United States, 2009-2011.
(2013) · PubMed Central · Cited by 293 · see citing works
What is a cohort effect? Comparison of three statistical methods for modeling cohort effects in obesity prevalence in the United States, 1971-2006
Keyes, K. M., Utz, R. L., Robinson, W., & Li, G. (2010) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.12.018 · Cited by 292 · see citing works
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Foley, D. L., & Morley, K. I. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2 · Cited by 283 · see citing works
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 272 · see citing works
Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006
Toth, P. P., Potter, D. M., & Ming, E. E. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.05.002 · Cited by 271 · see citing works
HbA1c 5·7–6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study
Heianza, Y., Hara, S., Arase, Y., Saito, K., Fujiwara, K., Tsuji, H., Kodama, S., Hsieh, S. D., Mori, Y., Shimano, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60472-8 · Cited by 260 · see citing works
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 232 · see citing works
Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity?
Li, C., Ford, E. S., Meng, Y., Mokdad, A. H., & Reaven, G. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-4 · Cited by 232 · see citing works
Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006
Hoang, U., Stewart, R., & Goldacre, M. J. (2011) · BMJ · doi:10.1136/bmj.d5422 · Cited by 222 · see citing works
Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study
Osby, U. (2000) · BMJ · doi:10.1136/bmj.321.7259.483 · Cited by 220 · see citing works
Weight and Thirty-Year Mortality of Men in the Framingham Study
Garrison, R. J., & CASTELLI, W. P. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-6-1006 · Cited by 219 · see citing works
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
Hert, M. A. F. D., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 216 · see citing works
Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207 · see citing works
Self-citation
Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005
Capasso, R., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & Sauver, J. L. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.005 · Cited by 201 · see citing works
Racial differences in glycemic markers: a cross-sectional analysis of community-based data
Selvin, E., Steffes, M. W., Ballantyne, C. M., Hoogeveen, R. C., Coresh, J., & Brancati, F. L. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00004 · Cited by 196 · see citing works
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182 · see citing works
Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking
Mucha, L., Stephenson, J., Morandi, N., & Dirani, R. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80216-0 · Cited by 169 · see citing works
Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades—a Danish nationwide study from 1980 to 2010
Nielsen, R. E., Uggerby, A. S., Jensen, S. O. W., & McGrath, J. J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.025 · Cited by 162 · see citing works
Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis
Mitchell, A. J., Lord, O., & Malone, D. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.094532 · Cited by 136 · see citing works
Revisiting the Hispanic mortality advantage in the United States: The role of smoking
Fenelon, A. T. (2013) · Social Science & Medicine · doi:10.1016/j.socscimed.2012.12.028 · Cited by 127 · see citing works
Prevalence of Chronic Kidney Disease in Persons With Undiagnosed or Prehypertension in the United States
Crews, D. C., Plantinga, L., Miller, E. R., Saran, R., Hedgeman, E., Saydah, S., Williams, D. E., & Powe, N. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.150722 · Cited by 123 · see citing works
Summary of Notifiable Noninfectious Conditions and Disease Outbreaks: Surveillance for Silicosis — Michigan and New Jersey, 2003–2010
Filios, M. S., Mazurek, J. M., Schleiff, P. L., Reilly, M. J., Rosenman, K. D., Lumia, M., & Worthington, K. (2015) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6254a6 · Cited by 117 · see citing works
Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients
Correll, C. U., Druss, B. G., Lombardo, I., O’Gorman, C., Harnett, J., Sanders, K. N., Alvir, J. M., & Cuffel, B. J. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.9.892 · Cited by 116 · see citing works
Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with Metabolic Syndrome: Implications for cardiovascular disease prevention
Sumner, A. E., Zhou, J., Doumatey, A. P., Imoisili, O. E., Amoah, A. G. B., Acheampong, J. W., Oli, J., Johnson, T., Adebamowo, C., & Rotimi, C. N. (2010) · Global Heart · doi:10.1016/j.cvdpc.2010.07.003 · Cited by 109 · see citing works
Avoidable mortality in people with schizophrenia or bipolar disorder in <scp>E</scp>ngland
Hoang, U., Goldacre, M. J., & Stewart, R. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12045 · Cited by 109 · see citing works
The Triglyceride Paradox in People of African Descent
Yu, S. S. K., Castillo, D. C., Courville, A. B., & Sumner, A. E. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0108 · Cited by 108 · see citing works
Review: Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis
Mitchell, A. J., & Lord, O. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382056 · Cited by 108 · see citing works
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
Lahti‐Pulkkinen, M., Tiihonen, J., Wildgust, H. J., Beary, M., Hodgson, R. E., Kajantie, E., Osmond, C., Räikkönen, K., & Eriksson, J. G. (2012) · Psychological Medicine · doi:10.1017/s0033291712000396 · Cited by 106 · see citing works
A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naive, First-Episode Psychosis Patients Treated With Haloperidol, Olanzapine, or Risperidone
Pérez‐Iglesias, R., & Crespo‐Facorro, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1113 · Cited by 104 · see citing works
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
Fleischhacker, W. W., SIU, C. O., Bodén, R., Pappadopulos, E. A., Karayal, O. N., Kahn, R. S., & the EUFEST study group (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001241 · Cited by 89 · see citing works
Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients
Correll, C. U. (2008) · International Review of Psychiatry · doi:10.1080/09540260801889179 · Cited by 85 · see citing works
Racial/Ethnic Differences in the Association of Triglycerides with Other Metabolic Syndrome Components: The Multi-Ethnic Study of Atherosclerosis
Lin, S. X., Carnethon, M. R., Szklo, M., & Bertoni, A. G. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0050 · Cited by 76 · see citing works
Guideline-Concordant Antipsychotic Use and Mortality in Schizophrenia
Cullen, B., McGinty, E. E., Zhang, Y., dosReis, S., Steinwachs, D. M., Güallar, E., & Daumit, G. L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs097 · Cited by 73 · see citing works
Should the Hemoglobin A 1c Diagnostic Cutoff Differ Between Blacks and Whites?
Tsugawa, Y., Mukamal, K. J., Davis, R. B., Taylor, W. C., & Wee, C. C. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-3-201208070-00004 · Cited by 72 · see citing works
Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness
Ratliff, J. C., Palmese, L. B., Reutenauer, E. L., Srihari, V. H., & Tek, C. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.03.001 · Cited by 71 · see citing works
Mortality and Its Determinants in People With Psychotic Disorder
Suvisaari, J., Partti, K., Perälä, J., Viertiö, S., Saarni, S. E., Lönnqvist, J. K., Saarni, S. I., & Härkänen, T. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31827ad512 · Cited by 63 · see citing works
Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill Patients With Schizophrenia
Kinon, B. J., Stauffer, V. L., Kollack‐Walker, S., Chen, L., & Sniadecki, J. L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818aaf6c · Cited by 61 · see citing works
Cardiovascular mortality in schizophrenia: Defining a critical period for prevention
Srihari, V. H., Phutane, V. H., Özkan, B., Chwastiak, L., Ratliff, J. C., Woods, S. W., & Tek, C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.014 · Cited by 58 · see citing works
Metabolic effects of second‐generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses
Moreno, C., Merchán‐Naranjo, J., Álvarez, M., Baeza, I., Alda, J. A., Martínez‐Cantarero, C., Parellada, M., Sánchez, B., de la Serna, E., Giráldez, M., et al. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00797.x · Cited by 54 · see citing works
The incidence and relative risk of stroke in patients with schizophrenia: A five-year follow-up study
Tsai, K., Lee, C., Chou, Y.-M., Su, C., & Chou, F. H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.013 · Cited by 54 · see citing works
Racial/ethnic variation in prevalence estimates for United States prediabetes under alternative 2010 American Diabetes Association criteria: 1988-2008.
Sentell, T. L., He, G., Gregg, E. W., & Schillinger, D. (2012) · PubMed · Cited by 33 · see citing works
Albert Einstein College of Medicine
Spiegel, A. M. (2008) · Academic Medicine · doi:10.1097/acm.0b013e31816bf1fd · Cited by 24 · see citing works
Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities
Correll, C. U., Harris, J. L., Moya, R. A. P., Frederickson, A. M., Kane, J. M., & Manu, P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.004 · Cited by 15 · see citing works
Adolescent BMI Trajectory and Risk of Diabetes versus Coronary Disease
Stockman, J. A. (2012) · Yearbook of Pediatrics · doi:10.1016/j.yped.2011.06.051 · Cited by 11 · see citing works
Prevalence of Chronic Kidney Disease in Persons With Undiagnosed or Prehypertension in the United States
Elliott, W. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2011.01.069 · Cited by 11 · see citing works
Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs
Manu, P., Correll, C. U., Wampers, M., van Winkel, R., Yu, W., Mitchell, A. J., & Binder, M. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.002 · Cited by 10 · see citing works

Flagged first, then by citations

Sorted by citations

Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · see citing works
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · see citing works
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036 · see citing works
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146 · see citing works
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729 · see citing works
Self-citation
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · see citing works
Self-citation
Comprehensive Versus Usual Community Care For First Episode Psychosis: Two-Year Outcomes From The NIMH RAISE Early Treatment Program
Kane, J., Robinson, D., Schooler, N., Mueser, K., Penn, D., Rosenheck, R., Addington, J., Brunette, M. F., Correll, C., Estroff, S., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15050632 · Cited by 756 · see citing works
Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P. A. P. M., Taipale, H. T., et al. (2022) · World Psychiatry · doi:10.1002/wps.20994 · Cited by 717 · see citing works
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Improving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575 · see citing works
Role of Insulin in Health and Disease: An Update
Rahman, M. S., Hossain, K. S., Das, S., Kundu, S., Adegoke, E. O., Rahman, M. A., Hannan, M. A., Uddin, M. J., & Pang, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126403 · Cited by 523 · see citing works
Cardiovascular disease in patients with severe mental illness
Nielsen, R. E., Banner, J., & Jensen, S. E. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00463-7 · Cited by 389 · see citing works
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292 · see citing works
Severe Mental Illness and Cardiovascular Disease
Goldfarb, M., Binder, M. D., Detraux, J., Palo, K. E. D., Munir, H., Music, S., Piña, I. L., & Ringen, P. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.017 · Cited by 250 · see citing works
The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta‐analysis
Stubbs, B., Vancampfort, D., Hert, M. D., & Mitchell, A. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12439 · Cited by 232 · see citing works
Loneliness in psychosis: a systematic review
Lim, M. H., Gleeson, J., Álvarez‐Jiménez, M., & Penn, D. L. (2018) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-018-1482-5 · Cited by 235 · see citing works
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A. F., Remington, G. J., Taylor, V. H., Müller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 206 · see citing works
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183 · see citing works
Association of Antihypertensive Drug Target Genes With Psychiatric Disorders
Chauquet, S., Zhu, Z., O’Donovan, M. C., Walters, J., Wray, N. R., & Shah, S. H. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0005 · Cited by 176 · see citing works
The epidemiology of diabetes in psychotic disorders
Ward, M., & Druss, B. G. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00007-3 · Cited by 151 · see citing works
Trends in Serious Psychological Distress and Outpatient Mental Health Care of US Adults
Olfson, M., Wang, S., Wall, M. M., Marcus, S. C., & Blanco, C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3550 · Cited by 140 · see citing works
Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program
Rosenheck, R. A., LESLIE, D. L., Sint, K., Lin, H., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Addington, J., Brunette, M. F., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv224 · Cited by 138 · see citing works
Shared Genetic Loci Between Body Mass Index and Major Psychiatric Disorders
Bahrami, S., Steen, N. E., Shadrin, A. A., O’Connell, K. S., Frei, O., Bettella, F., Wirgenes, K. V., Krull, F., Fan, C. C., Dale, A. M., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4188 · Cited by 132 · see citing works
Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: a longitudinal cohort study
Lee, R. S. C., Hermens, D. F., Naismith, S. L., Lagopoulos, J., Jones, A., Scott, J., Chitty, K. M., White, D., Robillard, R., Scott, E. M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.50 · Cited by 134 · see citing works
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults
Simon, G. E., Stewart, C. C., Yarborough, B. J. H., Lynch, F. W., Coleman, K. J., Beck, A. L., Operskalski, B. H., Penfold, R. B., & Hunkeler, E. M. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4437 · Cited by 124 · see citing works
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review
Mangurian, C. V., Newcomer, J. W., Modlin, C., & Schillinger, D. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3712-4 · Cited by 116 · see citing works
Exercise improves cardiorespiratory fitness in people with schizophrenia: A systematic review and meta-analysis
Vancampfort, D., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.09.029 · Cited by 113 · see citing works
Diet and Psychosis: A Scoping Review
Aucoin, M., LaChance, L., Cooley, K., & Kidd, S. A. (2018) · Neuropsychobiology · doi:10.1159/000493399 · Cited by 114 · see citing works
Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative
Dixon, L. B., Goldman, H. H., Srihari, V. H., & Kane, J. M. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084934 · Cited by 112 · see citing works
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes
Robinson, D. G., Gallego, J. A., John, M., Petrides, G., Hassoun, Y., Zhang, J., Lopez, L. V., Braga, R. J., Sevy, S. M., Addington, J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv125 · Cited by 112 · see citing works
Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span
Dieset, I., Andreassen, O. A., & Haukvik, U. K. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw028 · Cited by 108 · see citing works
Diabetes and Schizophrenia
Suvisaari, J., Keinänen, J., Eskelinen, S., & Mantere, O. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0704-4 · Cited by 123 · see citing works
Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis
Carney, R., Cotter, J., Bradshaw, T., Firth, J., & Yung, A. R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.010 · Cited by 104 · see citing works
Interventions for prodromal stage of psychosis
Kuharić, D. B., Kekin, I., Hew, J., Kuzman, M. R., & Puljak, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236.pub2 · Cited by 102 · see citing works
Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care
Moore, S., Shiers, D., Daly, B., Mitchell, A. J., & Gaughran, F. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12431 · Cited by 101 · see citing works
Schizophrenia and the retina: Towards a 2020 perspective
Silverstein, S. M., Fradkin, S. I., & Demmin, D. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.016 · Cited by 99 · see citing works
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99 · see citing works
Severe mental illness: cardiovascular risk assessment and management
Polcwiartek, C., O’Gallagher, K., Friedman, D. J., Correll, C. U., Solmi, M., Jensen, S. E., & Nielsen, R. E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae054 · Cited by 104 · see citing works
Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?
Joseph, J., Depp, C. A., Shih, P.-A. B., Cadenhead, K. S., & Schmid‐Schönbein, G. W. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00155 · Cited by 95 · see citing works
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88 · see citing works
Is It Possible to Predict the Future in First-Episode Psychosis?
Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T. J. S., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00580 · Cited by 88 · see citing works
Brexpiprazole: so far so good
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 84 · see citing works
Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States
Schoenbaum, M., Sutherland, J. M., Chappel, A. R., Azrin, S. T., Goldstein, A. B., Rupp, A. E., & HEINSSEN, R. K. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx009 · Cited by 82 · see citing works
Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia
Freyberg, Z., Aslanoglou, D., Shah, R. N., & Ballon, J. S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00432 · Cited by 82 · see citing works
Implementing evidence-based physical activity interventions for people with mental illness: an Australian perspective
Rosenbaum, S., Tiedemann, A., Stanton, R., Parker, A. G., Waterreus, A. J., Curtis, J., & Ward, P. B. (2015) · Australasian Psychiatry · doi:10.1177/1039856215590252 · Cited by 79 · see citing works
Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
Correll, C. U., Ng‐Mak, D., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., & Loebel, A. D. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0133-7 · Cited by 79 · see citing works
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone
Robinson, D. G., Gallego, J. A., John, M., Hanna, L. A., Zhang, J., Birnbaum, M. L., Greenberg, J., Naraine, M., Peters, B. D., McNamara, R. K., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.006 · Cited by 77 · see citing works
Cardiovascular effects of psychotic illnesses and antipsychotic therapy
Howell, S., Yarovova, E., Khwanda, A., & Rosen, S. D. (2019) · Heart · doi:10.1136/heartjnl-2017-312107 · Cited by 74 · see citing works
Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia
Bryll, A., Skrzypek, J., Krzyściak, W., Szelągowska, M., Śmierciak, N., Kozicz, T., & Popiela, T. J. (2020) · Biomolecules · doi:10.3390/biom10030384 · Cited by 73 · see citing works
A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis
Teasdale, S. B., Ward, P. B., Rosenbaum, S., Watkins, A., Curtis, J., Kalucy, M., & Samaras, K. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516001033 · Cited by 69 · see citing works
Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone
Noto, C. D. S., Ota, V., Gadelha, A., Noto, M. N., Barbosa, D. S., Bonifácio, K. L., Nunes, S. O. V., Cordeiro, Q., Belangero, S. I., Bressan, R. A., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.003 · Cited by 67 · see citing works
Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders
Chouinard, V., Pingali, S. M., Chouinard, G., Henderson, D. C., Mallya, S. G., Cypess, A. M., Cohen, B. M., & Öngür, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.024 · Cited by 64 · see citing works
Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis
Chouinard, V., Henderson, D. C., Man, C. D., Valeri, L., Gray, B. E., Ryan, K. P., Cypess, A. M., Cobelli, C., Cohen, B. M., & Öngür, D. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0045-1 · Cited by 62 · see citing works
Etiology of cardiovascular disease in patients with schizophrenia: current perspectives
Emül, M., & Kalelioğlu, T. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50006 · Cited by 61 · see citing works
Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth
Abidi, S., Mian, I. A., Ortega, I., Lecomte, T., Raedler, T. J., Jackson, K., Jackson, K., Pringsheim, T. M., & Addington, D. E. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720197 · Cited by 63 · see citing works
Brain insulin action in schizophrenia: Something borrowed and something new
Agarwal, S. M., Caravaggio, F., Costa-Dookhan, K. A., Castellani, L. N., Kowalchuk, C., Asgariroozbehani, R., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.010 · Cited by 59 · see citing works
Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis—A Longitudinal Study
McWhinney, S. R., Kolenič, M., Franke, K., Fialová, M., Knytl, P., Matějka, M., Španiel, F., & Hájek, T. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab064 · Cited by 57 · see citing works
Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis
Torres, N. G., Rocha-González, I., Alameda, L., Gangoso, A. R., Vilches, A., Canal‐Rivero, M., Crespo‐Facorro, B., & Ruíz-Veguilla, M. (2021) · Psychological Medicine · doi:10.1017/s0033291721002853 · Cited by 59 · see citing works
Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: Evidence for insulin resistance
Petrikis, P., Tigas, S. K., Tzallas, A. T., Papadopoulos, I. A., Skapinakis, P., & Mavreas, V. G. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.041 · Cited by 58 · see citing works
Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis
Nettis, M. A., Pergola, G., Kolliakou, A., O’Connor, J. A., Bonaccorso, S., David, A. S., Gaughran, F., Forti, M. D., Murray, R. M., Marques, T. R., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.09.005 · Cited by 56 · see citing works
Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
Ringen, P. A., Færden, A., Antonsen, B. T., Falk, R. S., Mamen, A., Rognli, E. B., Solberg, D. K., Andreassen, O. A., & Martinsen, E. W. (2018) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2018.1449012 · Cited by 56 · see citing works
A shared genetic contribution to breast cancer and schizophrenia
Lu, D., Song, J., Lu, Y., Fall, K., Chen, X., Fang, F., Landén, M., Hultman, C. M., Czene, K., Sullivan, P. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18492-8 · Cited by 53 · see citing works
Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls
Meier, M. H., Gillespie, N. A., Hansell, N. K., Hewitt, A. W., Hickie, I. B., Lu, Y., McGrath, J. J., MacGregor, S., Medland, S. E., Sun, C., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.045 · Cited by 53 · see citing works
Early-Life Adversity, Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life
Nettis, M. A., Pariante, C. M., & Mondelli, V. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_89 · Cited by 53 · see citing works
Retinal Microvasculature in Schizophrenia
Silverstein, S. M., Lai, A., Green, K. M., Crosta, C. M., Fradkin, S. I., & Ramchandran, R. S. (2021) · Eye and Brain · doi:10.2147/eb.s317186 · Cited by 51 · see citing works
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study
Morlán-Coarasa, M. J., Arias, M., de la Foz, V. O., Martínez‐García, O., Alonso-Martín, C., Crespo, J., Romero‐Gómez, M., Fábrega, E., & Crespo‐Facorro, B. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4422-7 · Cited by 50 · see citing works
Allostatic load and reduced cortical thickness in schizophrenia
Chiappelli, J., Kochunov, P. V., Savransky, A., Fisseha, F., Wisner, K., Du, X. M., Rowland, L. M., & Hong, L. E. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.021 · Cited by 51 · see citing works
Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium
Cadenhead, K. S., Minichino, A., Kelsven, S., Addington, J., Bearden, C. E., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Perkins, D. O., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.022 · Cited by 50 · see citing works
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J., Duncan, M. J., Takeuchi, H., Cohn, T. A., Taylor, V. H., Remington, G. J., Faulkner, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013337.pub2 · Cited by 47 · see citing works
Effects of childhood and adolescence physical activity patterns on psychosis risk—a general population cohort study
Sormunen, E., Saarinen, M. M., Salokangas, R. K. R., Telama, R., Hutri‐Kähönen, N., Tammelin, T., Viikari, J. S. A., Raitakari, O. T., & Hietala, J. A. (2017) · Schizophrenia · doi:10.1038/s41537-016-0007-z · Cited by 48 · see citing works
Group Lifestyle Intervention With Mobile Health for Young Adults With Serious Mental Illness: A Randomized Controlled Trial
Aschbrenner, K. A., Naslund, J. A., Gorin, A. A., Mueser, K. T., Browne, J., Wolfe, R. S., Xie, H., & Bartels, S. J. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202100047 · Cited by 47 · see citing works
Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade
Rødevand, L. N., Steen, N. E., Elvsåshagen, T., Quintana, D. S., Reponen, E. J., Mørch, R. H., Lunding, S. H., Vedal, T. S. J., Dieset, I., Melle, I. S., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13008 · Cited by 45 · see citing works
Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism
Misiak, B., Łaczmański, Ł., Słoka, N. K., Szmida, E., Piotrowski, P., Loska, O., Ślężak, R., Kiejna, A., & Frydecka, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.077 · Cited by 46 · see citing works
Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
Li, R., Zhang, Y., Zhu, W., Ding, C., Dai, W., Su, X., Dai, W., Xiao, J., Xing, Z., & Huang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-73983-4 · Cited by 43 · see citing works
Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders
Mothi, S. S., Tandon, N., Padmanabhan, J. L., Mathew, I. T., Clementz, B. A., Tamminga, C. A., Pearlson, G. D., Sweeney, J. A., & Keshavan, M. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.03.034 · Cited by 41 · see citing works
Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up
Nyboe, L., Vestergaard, C. H., Moeller, M. K., Lund, H., & Videbech, P. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.053 · Cited by 40 · see citing works
Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis
Gjerde, P. B., Dieset, I., Simonsen, C., Hoseth, E. Z., Iversen, T., Lagerberg, T. V., Lyngstad, S. H., Mørch, R. H., Skrede, S., Andreassen, O. A., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.042 · Cited by 40 · see citing works
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis
Vázquez-Bourgón, J., Pérez‐Iglesias, R., de la Foz, V. O., Pinilla, P. S., Díaz, Á., & Crespo‐Facorro, B. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4763-x · Cited by 39 · see citing works
Is autonomous motivation the key to maintaining an active lifestyle in first‐episode psychosis?
Vancampfort, D., Binder, M. D., Broderick, J. M., Lederman, O., Firth, J., Rosenbaum, S., & Probst, M. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12373 · Cited by 38 · see citing works
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 38 · see citing works
Renal Denervation Improves the Baroreflex and GABA System in Chronic Kidney Disease-induced Hypertension
Chen, H., Cheng, P., Ho, W.-Y., Lu, P., Lai, C.-C., Tseng, Y.-M., Fang, H.-C., Sun, G., Hsiao, M., Liu, C.-P., et al. (2016) · Scientific Reports · doi:10.1038/srep38447 · Cited by 38 · see citing works
Physical Health and Drug Safety in Individuals with Schizophrenia
Pringsheim, T. M., Kelly, M. A., Urness, D., Teehan, M. D., Ismail, Z., & Gardner, D. M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717719898 · Cited by 38 · see citing works
Elevated allostatic load early in the course of schizophrenia
Savransky, A., Chiappelli, J., Fisseha, F., Wisner, K., Xiaoming, D., Mirmomen, S. M., Jones, A. D., Adhikari, B. M., Bruce, H. A., Rowland, L. M., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0299-z · Cited by 39 · see citing works
Specialised early intervention teams for recent-onset psychosis
Puntis, S., Minichino, A., Crescenzo, F. D., Harrison, R., Cipriani, A., & Lennox, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013288.pub2 · Cited by 37 · see citing works
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Goh, K. K., Chen, C. Y.-A., Wu, T., Chen, C.-H., & Lu, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137092 · Cited by 37 · see citing works
Inflammation and metabolic changes in first episode psychosis: Preliminary results from a longitudinal study
Russell, A., Ciufolini, S., Gardner-Sood, P., Bonaccorso, S., Gaughran, F., Dazzan, P., Pariante, C. M., & Mondelli, V. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.06.004 · Cited by 37 · see citing works
Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Severe Mental Illness: A Systematic Review and Meta-analysis
Chan, J. K. N., Chu, R. S. T., Hung, C., Law, J. W. Y., Wong, C. S. M., & Chang, W. C. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac070 · Cited by 34 · see citing works
Schizoaffective disorder and metabolic syndrome: A meta-analytic comparison with schizophrenia and other non-affective psychoses
Bartoli, F., Crocamo, C., Caslini, M., Clerici, M., & Carrà, G. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.028 · Cited by 35 · see citing works
Monitoring of physical health in services for young people at ultra‐high risk of psychosis
Carney, R., Bradshaw, T., & Yung, A. R. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12288 · Cited by 35 · see citing works
Improving access to specialized care for first-episode psychosis: an ecological model
Moe, A. M., Rubinstein, E. B., Gallagher, C., Weiss, D. M., Stewart, A. M., & Breitborde, N. J. K. (2018) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s131833 · Cited by 35 · see citing works
Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
Galderisi, S., Binder, M. D., Prato, S. D., Fagiolini, A. M., Gorwood, P. A. P. M., Leucht, S., Maggioni, A. P., Mucci, A., & Arango, C. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2020.115 · Cited by 35 · see citing works
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 34 · see citing works
Clinical management of comorbid diabetes and psychotic disorders
Chwastiak, L., Freudenreich, O., Tek, C., McKibbin, C. L., Han, J., McCarron, R. M., & Wisse, B. E. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00105-4 · Cited by 33 · see citing works
Cardiometabolic health in young people with psychosis
Shiers, D., & Curtis, J. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00072-8 · Cited by 33 · see citing works
Prevalence of underweight in patients with schizophrenia: A meta-analysis
Sugawara, N., Maruo, K., Sugai, T., Suzuki, Y., Ozeki, Y., Shimoda, K., Someya, T., & Yasui‐Furukori, N. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.017 · Cited by 33 · see citing works
Treatment following myocardial infarction in patients with schizophrenia
Attar, R., Johansen, M. B., Valentin, J. B., Aagaard, J., & Jensen, S. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189289 · Cited by 33 · see citing works
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33 · see citing works

Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study
Addington, J., Penn, D. L., HEINSSEN, R. K., Correll, C. U., Estroff, S. E., Rosenheck, R. A., Goldstein, A., Kane, J. M., Schooler, N. R., Robinson, J., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/z250-m150 · Cited by 43 · see citing works
Journal Digest
Watts, V. (2015) · Psychiatric News · doi:10.1176/appi.pn.2015.1b1
Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment
Zhai, D., Cui, T., Xu, Y., Feng, Y., Wang, X., Yang, Y., Li, S., Zhou, D., Dong, G., Zhao, Y., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.09.001 · Cited by 25 · see citing works
Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis
Zierotin, A., Murphy, J., Stano, A., Norton, M. J., Cotter, D., Cannon, M. D., O’Connor, K., O'Donoghue, B. N., & Clarke, M. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag008
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1:Magnitude and Moderators of the Problem
Andrade, C. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16f10997 · Cited by 22 · see citing works

Authors: Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., Penn, D. L., Azrin, S., Goldstein, A., Severe, J., Heinssen, R., & Kane, J. M.
Affiliations: Northwell Health (US)
Geisel School of Medicine at Dartmouth, Dartmouth, New Hampshire7Bureau of Behavioral Health, Department of Health and Human Services, Dartmouth, New Hampshire
Boston University (US)
Yale University (US)
University of Calgary (CA)
University of North Carolina at Chapel Hill (US)
Nathan Kline Institute for Psychiatric Research (US)
National Institute of Mental Health (US)
ORCID: Correll, Christoph U.
Robinson, Delbert G.
Schooler, Nina R.
Brunette, Mary F.
Mueser, Kim T.
Rosenheck, Robert A.
Marcy, Patricia
Addington, Jean
Penn, David L.
Goldstein, Amy
Kane, John M.
Venue: JAMA Psychiatry
Publisher: American Medical Association (AMA)
Published: 2014-12-01
Volume: 71
Issue: 12
Pages: 1350
ISSN: 2168-622X (ISSN-L)
DOI: 10.1001/jamapsychiatry.2014.1314
OpenAlex: W2134164029
Cited by: 384
References: 88
Citations by year: 2026: 11 · 2025: 18 · 2024: 27 · 2023: 22 · 2022: 33 · 2021: 35 · 2020: 40 · 2019: 31 · 2018: 39 · 2017: 45 · 2016: 39 · 2015: 39 · 2014: 2 · 2013: 1
FWCI: 31.79
Type: journal article
Language: en
Open access: closed
Locations: JAMA Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Public Health Service (HHSN271200900019C)
National Institute of Mental Health (R03MH112053)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
Keywords: cardiometabolic risk, first-episode schizophrenia, schizophrenia spectrum disorders, antipsychotic treatment duration, olanzapine, metabolic syndrome, dyslipidemia, insulin resistance, prediabetes, obesity, smoking, hypertension, body composition, HDL cholesterol
MeSH terms: Adolescent, Adult, Blood Glucose, Body Composition, Cardiovascular Diseases, Ethnicity, Female, Humans, Insulin, Lipids, Male, Middle Aged, Obesity, Prospective Studies, Psychotic Disorders, Risk Factors, Schizophrenia, Sex Factors, Time Factors, Antipsychotic Agents, Metabolic Syndrome, Overweight, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks